<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02517489</url>
  </required_header>
  <id_info>
    <org_study_id>PHRN14-PFD/CAPE COD</org_study_id>
    <nct_id>NCT02517489</nct_id>
  </id_info>
  <brief_title>Community-Acquired Pneumonia : Evaluation of Corticosteroids</brief_title>
  <acronym>CAPE_COD</acronym>
  <official_title>Effects of Low-dose Corticosteroids on Survival of Severe Community-acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mortality of severe Community-Acquired Pneumonia (CAP) has not declined over time and is
      between 25 and 30% in sub-groups of patients. Corticosteroids (CTx) could down-regulate
      pulmonary and systemic inflammation, accelerate clinical resolution and decrease the rate of
      inflammation-associated systemic complications. Two recent meta-analyses suggest a positive
      effect on severe CAP day 28 survival when CTx are added to standard therapy. However they are
      based on only four trials gathering less than 300 patients, of which only one was positive.
      Recently published guidelines do not recommend CTx as part of CAP treatment. Therefore a
      well-powered trial appears necessary to test the hypothesis that CTx - and more specifically
      hydrocortisone - could improve day 28 survival of critically-ill patients with severe CAP,
      severity being assessed either on a Pulmonary Severity Index â‰¥ 130 (Fine class V) or by the
      use of mechanical ventilation or high-FiO2 high-flow oxygen therapy.

      A phase-III multicenter add-on randomized controlled double-blind superiority trial assessing
      the efficacy of hydrocortisone vs. placebo on Day 28 all-causes mortality, in addition to
      antibiotics and supportive care, including the correction of hypoxemia.

      Randomization will be stratified on: (i) centers; (ii) use of mechanical ventilation at the
      time of inclusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive state-of-the-art standard therapy for severe Community-Acquired
      Pneumonia (CAP), including antibiotics and supportive care. Correction of hypoxemia will use
      standard low-flow oxygen therapy, high-flow oxygen therapy, non-invasive-ventilation or
      invasive ventilation with endotracheal tube, as required. Patients in the treatment group
      will receive intra-venous hydrocortisone. Patients of the control group will receive an
      intravenous placebo by intravenous route at the same frequency.

      Hydrocortisone or placebo will be given in a double-blind fashion for 8 or 14 full days. The
      intravenous route will be used. The treatment course will include 4 or 7 days of full dose
      (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous
      infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of
      treatment is chosen upon patient initial improvement.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Day 28 all causes mortality</measure>
    <time_frame>at day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In patients non-invasively ventilated at inclusion, proportion of patients needing endotracheal intubation</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, for a maximum of 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In patients non-ventilated at inclusion, proportion of patients requiring non-invasive ventilation</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, for a maximum of 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In patients non-ventilated at inclusion, proportion of patients needing endotracheal intubation</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, for a maximum of 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 28 ventilator-free-days</measure>
    <time_frame>between 0 and day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with vasopressor therapy initiation from inclusion to day 28</measure>
    <time_frame>between 0 and day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 28 vasopressor-free-days</measure>
    <time_frame>between 0 and day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and/or intermediate care unit LOS</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, for a maximum of 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-causes mortality at day 90</measure>
    <time_frame>at day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 Health Survey at day 90</measure>
    <time_frame>at day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: procalcitonin at baseline, day 3 and day 7</measure>
    <time_frame>at inclusion, day 3 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: C-reactive protein at baseline, day 3 and day 7</measure>
    <time_frame>at inclusion, day 3 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: plasmatic concentration of pro-inflammatory cytokines (IL-6, IL-20, IL-22, IL-22BP, HBD2, TNF) at baseline, day 3 and day 7</measure>
    <time_frame>at inclusion, day 3 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P/F ratio measured daily from baseline to day 7, at the end of treatment, at the end of ICU-stay and/or day 28</measure>
    <time_frame>measured daily from baseline to day 7, at the end of treatment i.e 14 days after the start of treatment, at the end of ICU-stay (for a maximum of 28 days) and/or day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA calculated daily from baseline to day 7, at the end of treatment, at the end of ICU-stay and/or day 28</measure>
    <time_frame>calculated daily from baseline to day 7, at the end of treatment (i.e 14 days after the start of treatment), at the end of ICU-stay (for a maximum of 28 days) and/or day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients experiencing secondary infection during their ICU-stay</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, for a maximum of 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients experiencing gastrointestinal bleeding during their ICU-stay</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, for a maximum of 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily amount of insulin administered to the patient from day 1 to day 7</measure>
    <time_frame>Patients will be followed from day 1 to day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-gain at baseline and day 7</measure>
    <time_frame>Patients will be followed at baseline and day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Community Acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the treatment group will receive intra-venous hydrocortisone (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients of the control group will receive an intravenous placebo by intravenous route (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Hydrocortisone will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.</description>
    <arm_group_label>Hydrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years

          -  Patients affiliated to social security scheme

          -  Admission to an Intensive Care Unit (ICU) or intermediate care unit participating to
             the trial

          -  Diagnosis of Community- Acquired Pneumonia (CAP) suggested by at least two of the
             following: cough, purulent sputum, chest pain and dyspnea

          -  Focal shadowing/infiltrate on chest X-ray or CT-scan

          -  Diagnosis of Community- Acquired Pneumonia (CAP) during the 48 hours post-hospital
             admission

          -  Study drug infusion initiated no longer than 24 hours post first severity criterion

          -  Severity defined by at least one of the following:

               -  Pneumonia Severity Index (PSI) &gt; 130 (Fine class V)

               -  Patient placed on mechanical ventilation (invasive or not) for acute respiratory
                  failure, with a PEEP level of 5 cm of water or more

               -  Patient treated by high-flow oxygen therapy with a FiO2 of 50% or more and a
                  PaO2/FiO2 (P/F) ratio lower than 200

          -  Patient already treated by antibiotics (at least one dose)

          -  Informed consent signed by the patient, its relatives or emergency procedure

        Exclusion Criteria:

          -  Patient treated by vasopressors for septic shock at the time of inclusion

          -  Clinical history suggesting of aspiration of gastric content

          -  Patient treated by invasive mechanical ventilation within 14 days before current
             hospital admission

          -  Patient treated by antibiotics for a respiratory infection for more than five days at
             the admission to the hospital (except if a pathogen resistant to this antibiotics is
             isolated)

          -  History of cystic fibrosis

          -  Post-obstructive pneumonia

          -  Patients in which rapid PCR-test is positive for flu

          -  Active tuberculosis or fungal infection

          -  Active viral hepatitis or active infection with herpes viruses

          -  Myelosuppression

          -  Decision of withholding mechanical ventilation or endotracheal intubation

          -  Hypersensitivity to corticosteroids

          -  Patient needing anti-inflammatory corticosteroids or substitutive hydrocortisone for
             any reason

          -  Patients under treatment by more than 15 mg/d of prednisone (or equivalent) for more
             than 30 days

          -  Patient already enrolled in another drug trial

          -  Pregnant or breastfeeding woman

          -  Patient on judicial protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-FranÃ§ois DEQUIN, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de TOURS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre-FranÃ§ois DEQUIN, MD-PhD</last_name>
    <phone>02.47.47.38.55</phone>
    <phone_ext>+33</phone_ext>
    <email>pierre-franÃ§ois.dequin@univ-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie LECLERC</last_name>
    <phone>02.47.47.46.64</phone>
    <phone_ext>+33</phone_ext>
    <email>m.leclerc@chu-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de RÃ©animation - UnitÃ© de Soins Continus, CH d'AngoulÃªme</name>
      <address>
        <city>'AngoulÃªme</city>
        <zip>16959</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe CRACCO, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe CRACCO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation Polyvalente, CH d'Argenteuil</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GaÃ«tan PLANTEFEVE, MD</last_name>
    </contact>
    <investigator>
      <last_name>GaÃ«tan PLANTEFEVE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation HIA Clermont-Tonnerre</name>
      <address>
        <city>Brest</city>
        <zip>29240</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe GIACARDI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe GIACARDI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwann L'HER, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Erwann L'HER, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, HÃ´pital Louis Pasteur, Chartres</name>
      <address>
        <city>Chartres</city>
        <zip>28000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abdelkader OUCHENIR, MD</last_name>
    </contact>
    <investigator>
      <last_name>Abdelkader OUCHENIR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale Polyvalente, HÃ´pital G Montpied</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand SOUWEINE, MCU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Bertrand SOUWEINE, MCU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation, HÃ´pital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Damien RICARD, MCU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Damien RICARD, MCU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre QUENOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre QUENOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dico-Chirurgicale, HÃ´pital Raymond PoincarrÃ©, APHP</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Djillali ANNANE, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Djillali ANNANE, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas TERZI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas TERZI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation Polyvalente, CHD La Roche sur Yon</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean REIGNIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean REIGNIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation Polyvalente, HÃ´pital Salengro, CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MercÃ© JOURDAIN, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>MercÃ© JOURDAIN, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation Polyvalente, CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno FranÃ§ois, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bruno FranÃ§ois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, HÃ´pital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent PAPAZIAN, MCU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Laurent PAPAZIAN, MCU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation Polyvalente - Surveillance Continue, CH de Montauban</name>
      <address>
        <city>Montauban</city>
        <zip>82013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FrÃ©dÃ©ric BELLEC, MD</last_name>
    </contact>
    <investigator>
      <last_name>FrÃ©dÃ©ric BELLEC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SÃ©bastien GIBOT, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>SÃ©bastien GIBOT, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation Polyvalente, HÃ´pital HÃ´tel Dieu, CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe GUITTON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe GUITTON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, CHR d'OrlÃ©ans</name>
      <address>
        <city>OrlÃ©ans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry BOULAIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry BOULAIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, HÃ´pital Cochin, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Paul MIRA, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Paul MIRA, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation et USC mÃ©dico-chirurgicale, HÃ´pital Tenon, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muriel-Sarah FARTOUKH, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Muriel-Sarah FARTOUKH, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale et MÃ©decine Interne, CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre FRAT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre FRAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et RÃ©animation MÃ©dicale, CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud GACOUIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arnaud GACOUIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation Polyvalente, CH de Saint Malo</name>
      <address>
        <city>Saint Malo</city>
        <zip>35403</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>StÃ©phanie CHEVALIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>StÃ©phanie CHEVALIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas BARBAROT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas BARBAROT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, Nouvel HÃ´pital Civil, CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferhat MEZIANI, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ferhat MEZIANI, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale, HÃ´pital de Hautepierre, CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis SCHNEIDER, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Francis SCHNEIDER, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2015</study_first_submitted>
  <study_first_submitted_qc>August 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2015</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Community-Acquired Pneumonia (CAP)</keyword>
  <keyword>Hydrocortisone</keyword>
  <keyword>Corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

